| Literature DB >> 29600084 |
Luca Bertolaccini1, Alessandro Pardolesi1, Sergio Nicola Forti Parri1, Barbara Bonfanti1, Jury Brandolini2, Piergiorgio Solli1.
Abstract
In recent years, retrospective analyses have suggested that an oligometastatic state could exist, but the best evidence to date that a temporary oligometastatic disease exists for lung cancer mainly derives from the survival data on retrospective patients underwent surgical resection of a single M1 site and all intrathoracic disease. The critical determinates of long-term survival include definitive treatment of the primary non-small cell lung cancer (NSCLC), a single organ site of synchronous or metachronous disease, a long disease-free interval between treatment of the primary NSCLC and development of metastases, and the absence of intrathoracic lymph node (N0) disease. The ongoing development of innovative approaches to local therapy and treatment directed to the oligometastatic sites should be defined in future studies.Entities:
Keywords: Lung cancer; oligometastatic; thoracic surgery
Year: 2018 PMID: 29600084 PMCID: PMC5863206 DOI: 10.21037/jtd.2017.11.135
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895